10-Q: Exicure Inc. Reports Q2 2024 Results Amidst Strategic Review and Financial Uncertainty

Exicure Inc. released its Q2 2024 results, highlighting a strategic shift towards exploring alternatives and facing significant financial challenges.

Summary

• Exicure Inc. is an early-stage biotechnology company that has shifted its focus from developing nucleic acid therapies to exploring strategic alternatives to maximize stockholder value.
• The company is attempting to license its intellectual property and is exploring growth through transactions with potential partners.
• For the three months ended June 30, 2024, the company reported a net loss of $600,000, compared to a net loss of $5.764 million for the same period in 2023.
• For the six months ended June 30, 2024, the company reported a net loss of $1.429 million, compared to a net loss of $10.171 million for the same period in 2023.
• The company's cash and cash equivalents were $528,000 as of June 30, 2024, down from $816,000 at the end of 2023.
• The company has attempted to redeem $2 million in convertible notes receivable, but has not received a response and has written down the value of these notes to $0.
• Management has expressed substantial doubt about the company's ability to continue as a going concern due to insufficient cash and the need for substantial additional financing in the near term.

Sentiment

Score: 2

Explanation: The document paints a very negative picture of the company's financial health and future prospects, with significant risks and uncertainties. The company's ability to continue as a going concern is in doubt, and it faces potential delisting from Nasdaq.

Positives

• The company generated $500,000 in revenue from a patent license agreement.
• The company generated $637,000 in revenue from the sale of clinical samples.
• The company's net loss decreased significantly in both the three and six month periods ending June 30, 2024, compared to the same periods in 2023.
• The company has reduced its operating expenses by 78% in the three months ended June 30, 2024, compared to the same period in 2023.

Negatives

• The company's cash position has decreased to $528,000 as of June 30, 2024.
• The company has written down the value of its $2 million investment in convertible notes receivable to $0.
• There is substantial doubt about the company's ability to continue as a going concern without additional financing.
• The company is not in compliance with Nasdaq's minimum stockholders' equity requirement.
• The company has received a delisting determination from Nasdaq and must evidence compliance by September 16, 2024.

Risks

• The company's exploration of strategic alternatives may not be successful.
• The company needs to obtain substantial funding in the very near term to continue operations.
• The company may not be able to redeem its investment in convertible notes receivable.
• The company's controlling stockholders and management have limited experience with U.S. public companies.
• Turnover of the board and senior management could impair the company's ability to implement its business plan.
• The company may be delisted from Nasdaq, which could negatively impact the price of its common stock.
• The company has a history of losses and may never achieve or maintain profitability.
• The company's internal computer systems may fail or suffer security breaches.
• The company's operations are concentrated in one location, which could be disrupted by unforeseen events.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company's stock price is highly volatile and may decline.
• The company's ability to use net operating loss carryforwards may be limited.

Future Outlook

The company's future is uncertain, with a focus on exploring strategic alternatives and a need for substantial additional financing in the very near term. The company's ability to continue as a going concern is in doubt without additional funding.

Management Comments

• Management believes that, given the Company's current cash position, operating plans and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date these financial statements are issued.
• Management does not believe the Notes Receivable are recoverable and they have been written down to $0 on our balance sheet.

Industry Context

The company's shift from research and development to exploring strategic alternatives reflects the challenges faced by early-stage biotechnology companies in securing funding and achieving commercial success. The company's focus on licensing its intellectual property is a common strategy for companies in this sector.

Comparison to Industry Standards

• Exicure's financial situation is significantly worse than many comparable publicly traded biotechnology companies, many of which have substantial cash reserves and ongoing revenue streams.
• Many comparable companies are actively engaged in clinical trials and have a clear path to commercialization, while Exicure has suspended its research and development activities.
• Companies such as Alnylam Pharmaceuticals and Ionis Pharmaceuticals, which also focus on nucleic acid therapies, have significantly larger market capitalizations and more robust financial positions.
• Exicure's current situation is more comparable to companies that are in the process of restructuring or facing bankruptcy, rather than those actively developing and commercializing new therapies.

Legal Proceedings

• The company is involved in a securities class action lawsuit, which has reached an agreement in principle to settle.
• The company is also involved in multiple shareholder derivative lawsuits.
• A former employee has filed a complaint against the company and its executives.

Related Party Transactions

• The company executed a promissory note with DGP, a related party, and received a loan of $700,000.

Stakeholder Impact

• Shareholders face significant risk of losing their investment due to the company's financial instability and potential delisting.
• Employees face uncertainty about their jobs due to the company's financial challenges and potential restructuring.
• Customers and suppliers may be impacted by the company's potential cessation of operations.

Next Steps

• The company will continue to explore strategic alternatives.
• The company will attempt to raise additional capital.
• The company will seek stockholder approval for a reverse stock split.
• The company must evidence compliance with Nasdaq listing requirements by September 16, 2024.

Key Dates

Keywords

strategic alternatives, biotechnology, licensing, financial results, going concern, capital raise, Nasdaq, delisting, convertible notes, internal controls